Total Payments
$9,827
2024 Payments
$2,319
Companies
29
Transactions
70
Medicare Patients
763
Medicare Billing
$139,515
Payment Breakdown by Category
Research$4,697 (47.8%)
Other$3,295 (33.5%)
Food & Beverage$1,639 (16.7%)
Travel$136.11 (1.4%)
Education$59.99 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,697 | 4 | 47.8% |
| Honoraria | $2,025 | 1 | 20.6% |
| Food and Beverage | $1,639 | 61 | 16.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,270 | 2 | 12.9% |
| Travel and Lodging | $136.11 | 1 | 1.4% |
| Education | $59.99 | 1 | 0.6% |
Payments by Type
General
$5,130
66 transactions
Research
$4,697
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $5,918 | 9 | $0 (2023) |
| Coherus Biosciences Inc. | $2,177 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $227.27 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $167.28 | 5 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $160.74 | 9 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $149.85 | 2 | $0 (2022) |
| SOBI, INC | $126.06 | 5 | $0 (2023) |
| Amgen Inc. | $111.90 | 5 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $103.58 | 4 | $0 (2024) |
| Incyte Corporation | $100.57 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,319 | 8 | Coherus Biosciences Inc. ($2,177) |
| 2023 | $4,674 | 12 | PFIZER INC. ($4,470) |
| 2022 | $213.99 | 9 | Sobi, Inc ($105.02) |
| 2021 | $12.54 | 1 | Dova Pharmaceuticals ($12.54) |
| 2020 | $103.45 | 6 | Merck Sharp & Dohme Corporation ($36.33) |
| 2019 | $2,006 | 21 | PFIZER INC. ($1,419) |
| 2018 | $392.46 | 10 | E.R. Squibb & Sons, L.L.C. ($132.44) |
| 2017 | $105.71 | 3 | Incyte Corporation ($59.99) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Honoraria | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | Cash or cash equivalent | $152.02 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Immunology | ||||||
| 01/31/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Immunology | ||||||
| 12/20/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $30.71 | General |
| 12/19/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.91 | General |
| 12/12/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | ELREXFIO | — | In-kind items and services | $3,200.00 | Research |
| Study: GEDATOLISIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/27/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.50 | General |
| Category: Oncology | ||||||
| 06/02/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/12/2023 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug), Nubeqa | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Oncology | ||||||
| 03/10/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Oncology | ||||||
| 02/16/2023 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Genetic Disease | ||||||
| 02/14/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ELRANATAMAB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/09/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Oncology | ||||||
| 01/12/2023 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $20.65 | General |
| Category: Oncology | ||||||
| 12/15/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 10/10/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.93 | General |
| Category: Hematology/Oncology | ||||||
| 09/07/2022 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Oncology | ||||||
| 08/08/2022 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY TO INVESTIGATE THE SAFETY | GlaxoSmithKline, LLC. | $227.27 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 209 | 529 | $181,395 | $39,295 |
| 2022 | 6 | 206 | 518 | $170,935 | $38,837 |
| 2021 | 6 | 187 | 463 | $145,260 | $34,306 |
| 2020 | 6 | 161 | 383 | $132,065 | $27,077 |
Total Patients
763
Total Services
1,893
Medicare Billing
$139,515
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 71 | 299 | $119,600 | $23,823 | 19.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 92 | $15,640 | $6,107 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 45 | 77 | $21,175 | $3,704 | 17.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 29 | 29 | $17,400 | $2,983 | 17.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 13 | $4,160 | $1,432 | 34.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 19 | $3,420 | $1,245 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 249 | $99,600 | $20,554 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 44 | 121 | $33,275 | $6,882 | 20.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 76 | $12,920 | $4,642 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $13,200 | $2,590 | 19.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 21 | $6,720 | $2,428 | 36.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 25 | 29 | $5,220 | $1,741 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 177 | $70,800 | $14,561 | 20.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 43 | 120 | $33,000 | $6,912 | 20.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 34 | 102 | $17,340 | $6,189 | 35.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 25 | 27 | $8,640 | $3,159 | 36.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 21 | 21 | $12,600 | $2,481 | 19.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 13 | 16 | $2,880 | $1,004 | 34.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 65 | 226 | $90,400 | $15,557 | 17.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 32 | 82 | $13,940 | $5,182 | 37.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 24 | 24 | $14,400 | $2,710 | 18.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 14 | $4,480 | $1,688 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 16 | 23 | $6,325 | $1,035 | 16.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 14 | $2,520 | $904.40 | 35.9% |
About Jacob Thomas
Jacob Thomas is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2012. The National Provider Identifier (NPI) number assigned to this provider is 1811262967.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jacob Thomas has received a total of $9,827 in payments from pharmaceutical and medical device companies, with $2,319 received in 2024. These payments were reported across 70 transactions from 29 companies. The most common payment nature is "" ($4,697).
As a Medicare-enrolled provider, Thomas has provided services to 763 Medicare beneficiaries, totaling 1,893 services with total Medicare billing of $139,515. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Los Angeles, CA
- Active Since 03/21/2012
- Last Updated 11/27/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811262967
Products in Payments
- LOQTORZI (Biological) $2,177
- ELREXFIO (Drug) $1,270
- BAVENCIO (Drug) $165.11
- KEYTRUDA (Biological) $124.14
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $117.87
- DOPTELET (Drug) $105.02
- Braftovi (Drug) $81.49
- Neulasta (Biological) $78.31
- Lonsurf (Drug) $66.18
- OPDIVO (Biological) $50.19
- Fabhalta (Drug) $49.96
- Lenvima (Drug) $45.46
- Creon (Drug) $37.14
- Doptelet (Drug) $33.58
- LIBTAYO (Biological) $31.98
- DARZALEX (Biological) $25.74
- UNITUXIN (Drug) $24.48
- CABOMETYX (Drug) $24.10
- ALOXI (Drug) $23.75
- GIVLAARI (Drug) $23.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334